Head-To-Head Contrast: Envoy Medical (NASDAQ:COCH) & RxSight (NASDAQ:RXST)

RxSight (NASDAQ:RXST) and Envoy Medical (NASDAQ:COCH) are both small-cap healthcare companies, but which is the superior business? We will compare the two companies based on the strength of their analyst recommendations, profitability, valuation, institutional ownership, earnings, dividends and risk.

Earnings and Valuation

This table compares RxSight and Envoy Medical”s revenue, earnings per share (EPS) and valuation.

	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
RxSight	$134.48 million	1.45	-$38.94 million	($1.13)	-4.15
Envoy Medical	$207,000.00	247.99	-$23.76 million	($0.76)	-0.88

Envoy Medical has lower revenue, but higher earnings than RxSight. RxSight is trading at a lower price-to-earnings ratio than Envoy Medical, indicating that it is currently the more affordable of the two stocks.

Risk & Volatility

RxSight has a beta of 1.15, indicating that its stock price is 15% more volatile than the S&P 500. Comparatively, Envoy Medical has a beta of 1.97, indicating that its stock price is 97% more volatile than the S&P 500.

Analyst Recommendations

This is a summary of recent ratings and price targets for RxSight and Envoy Medical, as provided by MarketBeat.

	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
RxSight	3	7	2	0	1.92
Envoy Medical	1	1	2	0	2.25

RxSight currently has a consensus price target of $8.17, indicating a potential upside of 74.06%. Envoy Medical has a consensus price target of $2.17, indicating a potential upside of 225.81%. Given Envoy Medical’s stronger consensus rating and higher possible upside, analysts clearly believe Envoy Medical is more favorable than RxSight.

Profitability

This table compares RxSight and Envoy Medical’s net margins, return on equity and return on assets.

	Net Margins	Return on Equity	Return on Assets
RxSight	-36.80%	-17.35%	-14.70%
Envoy Medical	-11,304.83%	N/A	-144.13%

Insider & Institutional Ownership

78.8% of RxSight shares are owned by institutional investors. Comparatively, 8.6% of Envoy Medical shares are owned by institutional investors. 10.1% of RxSight shares are owned by company insiders. Comparatively, 7.2% of Envoy Medical shares are owned by company insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a stock is poised for long-term growth.

Summary

Envoy Medical beats RxSight on 8 of the 13 factors compared between the two stocks.

About RxSight

RxSight, Inc., a commercial-stage medical device company, engages in the research and development, manufacture, and sale of light adjustable intraocular lenses (LAL) used in cataract surgery in the United States and internationally. It offers RxSight system that enables doctors to customize and enhance the visual acuity for patients after cataract surgery. The company's RxSight system includes RxSight Light Adjustable Lens, a special photosensitive material that changes shape and power. RxSight light delivery device, an office-based light treatment device that delivers UV light in a programmed pattern to modify the LAL based on the visual correction needed to achieve desired vision after cataract surgery. It primarily serves cataract doctors. The company was formerly known as Calhoun Vision, Inc. and changed its name to RxSight, Inc. in February 2017. RxSight, Inc. was incorporated in 1997 and is headquartered in Aliso Viejo, California.

About Envoy Medical

Envoy Medical, Inc., a hearing health company, provides medical technologies for the hearing loss spectrum. Its products include personal sound amplification devices; hearing aids; Esteem fully implanted active middle ear implants; auditory osseointegrated implants; and Acclaim cochlear implants. The company was formerly known as Envoy Medical Corporation and changed its name to Envoy Medical, Inc. in September 2023. Envoy Medical, Inc. was founded in 1995 and is headquartered in White Bear Lake, Minnesota.